// App-Quantinova.ai

5004 : ERG rearrangements and association with clinical outcome in patients (pts) receiving abiraterone acetate (AA): Results from the COU-AA-302 study in chemotherapy (chemo)-nave metastatic castration-resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Gerhardt Attard

Principal Investigators

  • Johann Sebastian De Bono

  • Weimin Li

  • Arturo Molina

  • Thomas W. Griffin

  • Thian San Kheoh

  • Deborah Sokol Ricci

  • Kathy Zelinsky

  • Dana E. Rathkopf

  • Howard I. Scher

  • Charles J. Ryan

Medical Centers

  • Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Janssen Research & Development, Los Angeles, CA

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

  • Janssen Research & Development, LLC, Raritan, NJ

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Prostate specific antigen

  • ETS transcription factor ERG

Drug/Treatment

  • CB-7598

  • Prednisone

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT00887198

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved